Vanderbilt researchers have been awarded two five-year federal grants totaling $51 million to harness new and existing approaches for boosting recruitment and removing roadblocks to the efficiency of conducting clinical trials throughout the country.

A multi-institutional study found that low-dose atropine eyedrops, commonly used in a higher dose to treat lazy eye, was no better than a placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years.

Researchers in Vanderbilt's Implantables, Hearing Enhancement and Amplification Research Laboratory have launched a study of neuroplasticity, or the brain’s ability to adapt to new information, in cochlear implant outcomes.

Vanderbilt University Medical Center has received a $7 million, five-year funding award from the Patient-Centered Outcomes Research Institute to compare two sedatives used to place breathing tubes in the emergency department or intensive care unit.

Many low-risk patients with a penicillin allergy were able to have their penicillin allergy label removed through a simple procedure known as “direct oral challenge” as part of a world-first multicenter randomized control trial known as the Penicillin Allergy Clinical Decision Rule (PALACE) study.

Together with the Vanderbilt Kennedy Center and ACM Lifting Lives, SENSE Theatre recently presented a two-night performance of the play Circus del Sé, written by Blythe Corbett, PhD, James G. Blakemore Professor of Psychiatry and Behavioral Sciences.

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.